Search - tctmd.com

Displaying 21 - 40 of 42

Sort: Relevancy | Date

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

News Daily News

Minimalist Valve-in-Valve TMVR as Safe as Conventional Approach

Michael O'Riordan

June 21, 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Conference News PCR London Valves 2021

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

Michael O'Riordan

November 26, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2021

Shelley Wood

August 02, 2021

News Daily News

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

L.A. McKeown

June 03, 2021

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

Shelley Wood

May 15, 2021

News Daily News

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

Michael O'Riordan

April 15, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2021

Shelley Wood

February 03, 2021

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

Caitlin E. Cox

January 01, 2019

Presentation TCT Abstracts Posters 2018

Coronary Artery Calcium in Heart Failure with Preserved Ejection Fraction Patients: More Serious Than We Think

Presenter: Abdalla Hassan

September 25, 2018

News Daily News

Yet Another Set of Hypertension Guidelines Sow Confusion Surrounding BP Targets in Older Patients

Michael O'Riordan

January 17, 2017

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Industry News

NanoCor Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) for Carfostin®

April 20, 2016

Advertisement

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Minimalist Valve-in-Valve TMVR as Safe as Conventional Approach

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

TCTMD’s Top 10 Most Popular Stories for July 2021

Moderate Aortic Stenosis and HFrEF Combo Portends Poor Survival, Study Finds

‘Enormous’ QoL Improvements With Mavacamten in HCM

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

TCTMD’s Top 10 Most Popular Stories for January 2021

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

TCTMD’s Top 10 Most Popular Stories for December 2018

Coronary Artery Calcium in Heart Failure with Preserved Ejection Fraction Patients: More Serious Than We Think

Yet Another Set of Hypertension Guidelines Sow Confusion Surrounding BP Targets in Older Patients

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

NanoCor Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) for Carfostin®

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content